首页> 外文期刊>Journal of cardiovascular translational research >Impact of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio on 5-Year Clinical Outcomes of Patients with Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention
【24h】

Impact of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio on 5-Year Clinical Outcomes of Patients with Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention

机译:中性粒细胞对淋巴细胞比和血小板到淋巴细胞比率对稳定冠状动脉疾病患者5年临床结果的影响

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The prognostic role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with stable coronary artery disease (CAD) is still unclear. We enrolled 500 patients undergoing elective percutaneous coronary intervention (PCI). Blood samples were drawn prior to PCI for NLR and PLR calculation. Major adverse clinical events (MACE), which included death, myocardial infarction (MI), and target vessel revascularization (TVR), were recorded up to 5years. Patients in the higher tertile of NLR presented higher Kaplan-Meier estimates of MACE (26.0% vs. 16.9% in tertile 2 vs. 14.3% in tertile 1; p=0.042) and death (12.0% vs 6.9% in tertile 2 vs. 4.6% in tertile 1; p=0.040), whereas there were no significant differences in the estimates of MI and TVR. NLR in the higher tertile was an independent predictor of MACE (HR 1.65, 95% CI 1.07-2.55, p=0.024). No significant difference was observed across tertiles of PLR. Unlike PLR, elevated pre-procedural NLR is associated with an increased risk of 5-year clinical adverse events.
机译:中性粒细胞对淋巴细胞比(NLR)和血小板到淋巴细胞比(PLR)稳定冠状动脉疾病(CAD)患者的预后作用尚不清楚。我们注册了500名接受精神经审冠状动脉干预(PCI)的患者。在PCI之前绘制血液样品,用于NLR和PLR计算。包含死亡,心肌梗死(MI)和靶血管血运重建(TVR)的主要不良临床活动(MACE)被记录到5年。 NLR较高的患者呈现出升高的KAPLAN-MEIER估算术(26.0%与Tertile 2的16.9%,在Tertile 1中的14.3%)和死亡(Tertile 2的12.0%Vs 6.9%。 4.6%在Tertive 1; P = 0.040),而MI和TVR的估计没有显着差异。在较高的Tertile中的NLR是术的独立预测因子(HR 1.65,95%CI 1.07-2.55,P = 0.024)。跨PLR的泰利物没有观察到显着差异。与PLR不同,升高的前程序NLR与5年临床不良事件的风险增加有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号